Dermatofibrosarcoma protuberans - An update

JDDG - Journal of the German Society of Dermatology

Volumn 2, Issue 8, 2004, Pages 661-667

  Breuninger, Helmut ^a   Sebastian, Günther ^b   Garbe, Claus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

3 D histology; Dermatofibrosarcoma protuberans; Histographic micrographic surgery; Imatinib

Indexed keywords

BLOOD CLOTTING FACTOR 8A; CD34 ANTIGEN; COLLAGEN TYPE 1; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHROMOSOME 17Q; CHROMOSOME 22Q; CHROMOSOME TRANSLOCATION; COMPUTER ASSISTED TOMOGRAPHY; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIAL DIAGNOSIS; GENE LOCUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PROGNOSIS; REVIEW; RING CHROMOSOME;

DERMATOFIBROSARCOMA; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 6044240880     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0353.2004.04056.x     Document Type: Review

References (50)

1. Fletcher CD, Evans BJ, MacArtney JC, Smith N, Wilson Jones E, McKee PH Dermatofibrosarcoma protuberans: a clinicopathological and immunohistochemical study with a review of the literature. Histopathology 1985; 9: 921-938.
2. Weiss SW. Histological typing of soft tissue tumours, WHO International Histological Classification of Tumours, 2nd Edition, Springer, Berlin, Heidelberg, New York, Tokyo, 1994.
3. Koh CK, Ko CB, Bury HP, Wyatt EH. Dermatofibrosarcoma protuberans. Int J Dermatol 1995; 34: 256-260.
4. Lopes JM, Paiva ME. Dermatofibrosarcoma protuberans. A histological and ultrastructural study of 11 cases with emphasis on the study of recurrences and histogenesis. Pathol Res Pract 1991; 187: 806-813.
5. Smola MG, Soyer HP, Scharnagl E. Surgical treatment of dermatofibrosarcoma protuberans. A retrospective study of 20 cases with review of literature. Eur J Surg Oncol 1991; 17: 447-453.
6. Breuninger H, Thaller A, Schippert W. Die subklinische Ausbreitung des Dermatofibrosarkoma protuberans (DFSP) und daraus resultierende Behandlungsmodalitäten. Hautarzt 1994; 45: 541-545.
7. Martin L, Combemale P, Dupin M, Chouvet B, Kanitakis J, Bouyssou-Gauthier ML, Dubreuil G, Claudy A, Grimand PS. The atrophic variant of dermatofibrosarcoma protuberans in childhood: a report of six cases. Br J Dermatol 1998; 139: 719-725.
8. Weinstein JM, Drolet BA, Esterly NB, Rogers M, Bauer BS, Wagner AM, Mancini AJ. Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol 2003; 139: 207-211.
9. Smookler B. Giant cell fibroblastoma. A juvenile form of dermatofibrosarcoma protuberans. Cancer 1989; 64: 2154-2161.
10. Perry D, Schultz L, Dehner L. Giant all fibroblastoma with dermatofibrosarcoma protuberans-like transformation. J Cutan Pathol 1993; 20: 451-454.
11. Lal P, Sharma R, Mohan H, Sekhon MS. Dermatofibrosarcoma protuberans metastasizing to lymph nodes: a case report and review of literature. J Surg Oncol 1999; 72: 178-180.
12. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: A reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol 2000; 24: 1125-1130.
13. Mentzel T, Beham A, Katenkamp D, Dei TA, Fletcher CD. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998; 22: 576-587.
14. Minter RM, Reith JD, Hochwald SN. Metastatic potential of dermatofibrosarcoma protuberans with fibrosarcomatous change. J Surg Oncol 2003; 82: 201-208.
15. Nishio J, Iwasaki H, Ohjimi Y, Ishiguro M, Isayama T, Naito M, Iwashita A, Kikuchi M. Overrepresentation of 17q22-qter and 22q13 in dermatofibrosarcoma protuberans but not in dermatofibroma: a comparative genomic hybridization study. Cancer Genet Cytogenet 2002; 132: 102-108.
16. Navarro M, Simon MP, Migeon C, Turc-Carel C, Pedeutour F. COL1A1-PDGFB fusion in a ring chromosome 4 found in a dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 1998; 23: 263-266.
17. O'Brien KP, Seroussi E, Dal Cin P, Sciot R, Mandahl N, Fletcher JA, Turc-Carel C, Dumanski JP. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998; 23: 187-193.
18. Simon MP. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gen COL 1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15: 95-98.
19. Simon MP, Navarro M, Roux D, Pouyssegur J. Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t (17;22) (q22;q13.1) in dermatofibrosarcoma protuberans (DP). Oncogene 2001; 20: 2965-2975.
20. Weiss SW, Goldblum JR. Fibrohistiocytic tumors of intermediate malignancy. In: Weiss SW, Goldblum JR (Editors): Enzinger and Weiss's Soft Tissue Tumors. St. Louis, MO, Mosby 2001: 491-506.
21. Kamino H, Reddy VB, Greco MA. Dermatomyofibroma, a benign cutaneous plaque-like proliferation of fibroblasts and myofibroblasts in young adults. J Cutan Pathol 1992; 19: 85-93.
22. Abenoza P, Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol 1993; 15: 429-434.
23. Kutzner H. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue. J Am Acad Dermatol 1993; 28: 613-617.
24. Reis-Filho JS, Milanezi F, Ferro J, Schmitt FC. Pediatric pigmented dermatofibrosarcoma protuberans (Bednar tumor): case report and review of the literature with emphasis on the differential diagnosis. Pathol Res Pract 2002; 198: 621-626.
25. Dupree WB, Langloss JM, Weiss SW. Pigmented dermatofibrosarcoma protuberans (Bednar tumor). A pathologic, ultrastructural, and immunohistochemical study. Am J Surg Pathol 1985; 9: 630-639.
26. Fletcher CD, Theaker JM, Flanagan A, Krausz T. Pigmented dermatofibrosarcoma protuberans (Bednar tumour): melanocytic colonization or neuroectodermal differentiation? A clinicopathological and immunohistochemical study. Histopathology 1988; 13: 631-643.
27. Ohtani N, Fukusato T, Tezuka F. Sarcomatous dermatofibrosarcoma protuberans metastasized to the lung: preservation of CD34 expression in tumor cells. Pathol Int 1998; 48: 989-993.
28. Zamecnik M, Michal M, Mukensnabl P. Composite tumor consisting of dermatofibrosarcoma protuberans and myxofibrosarcoma. J Cutan Pathol 1998; 25: 445-449.
29. Orlandi A, Bianchi L, Spagnoli LG. Myxoid dermatofibrosarcoma protuberans: morphological, ultrastructural and immunohistochemical features. J Cutan Pathol 1998; 25: 386-393.
30. Zamecnik M, Michal M, Baumruk L, Mukensnabl P. Dermatofibrosarcoma protuberans with EMa+ cells. Report of a case suggesting perineurial cell differentiation. Pathol Res Pract 2003; 198: 767-774.
31. Parker TL, Zitelli JA. Surgical margins for excision of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1995; 32: 233-236.
32. Ratner D, Thomas CO, Johnson TM. Mohs micrographic surgery for die treatment of dermatofibrosarcoma protuberans. Results of a multi-institutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997; 37: 600-613.
33. Kosanke U. Ergebnisse der Therapie des Dermatofibrosarkoma protuberans mit Hilfe der mikrographisch kontrollierten Chirurgie. Dissertation, Humboldt-Universität, Berlin, 1999.
34. Breuninger H., Schaumburg-Lever G. Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours: An alternative to Mohs' technique. Brit J Pathol 1988; 154: 167-171.
35. Massey RA, Tok J, Strippoli BA, Szabolcs MJ, Silvers DN, Eliezri Y. A comparison of frozen and paraffin sections in dermatofibrosarcoma protuberans. Dermatol Surg 1998; 24: 995-998.
36. Jimenez FJ, Grichnik JM, Buchanan MD, Clark RE. Immunohistochemical margin control applied to Mohs micrographic surgical excision of dermatofibrosarcoma protuberans. J Dermatol Surg Oncol 1994; 20: 687-689.
37. Gloster HM, Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35: 82-87.
38. Ah-Weng A, Marsden JR, Sanders DS, Waters R. Dermatofibrosarcoma protuberans treated by micrographic surgery. Br J Cancer 2002; 87: 1386-1389.
39. Nouri K, Lodha R, Jimenez G, Robins P. Mohs micrographic surgery for dermatofibrosarcoma protuberans: University of Miami and NYU experience. Dermatol Surg 2002; 28: 1060-1064.
40. Steinat D, Breuninger H. Surgical therapeutic concept with 3-D-histology of the dermatofibrosarcoma protuberans in 96 patients. 2. Joint Meeting EADO, GCC, ADO, AMDO Marseille, 2003.
41. Rowsell AR, Poole MD, Godfrey AM. Dermatofibrosarcoma protuberans: the problems of surgical management. Br J Plast Surg 1986; 39: 262-264.
42. Caetano M. Dermatofibrosarcoma protuberans, review of 16 cases. Skin Cancer 2003; 18: 21-28.
43. Vandeweyer E, De Saint A, Gebhart M. Dermatofibrosarcoma protuberans: how wide is wide in surgical excision? Acta Chir Belg 2002; 102: 455-458.
44. Ballo MT, Zagars GK, Pisters P, Pollack A. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998; 40: 823-827.
45. Marks LB, Suit HD, Rosenberg AE, Wood WC. Dermatofibrosarcoma protuberans treated with radiation therapy. Int J Radiat Oncol Biol Phys 1989; 17: 379-384.
46. Sun LM, Wang CJ, Huang CC, Leung SW, Chen HC, Fang FM, Huang EY, Lee SP. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000; 57: 175-181.
47. Sjoblom T. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI 571 through induction of apoptosis. Cancer Res 2001; 61: 5778-5783.
48. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003; 37: 1-19.
49. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002; 100: 623-626.
50. Breuninger H, Hobbach PS, Schimek F. Ropivacaine: An important anesthetic agent for slow infusion and other forms of tumescent anesthesia. J Dermatol Surg 1999; 25: 799-802.